Skip to main content
. 2016 Apr 19;8(4):267–275. doi: 10.1177/1758834016642370

Figure 1.

Figure 1.

Cytochrome P450 (CYP) 17 inhibitors targeting androgen synthesis and androgen receptors (ARs), currently approved and those in advanced stages of clinical development in castration-sensitive or -resistant prostate cancer. Thick arrows denote stimulation, flat lines denote inhibition, and thin arrows denote synthesis. DHEA, dehydroepiandrosterone; DHT, dihydroxy testosterone.